Although women with estrogen receptor–positive breast cancer who were not treated with tamoxifen would be the most appropriate control group for the tamoxifen group, such enrollment might be difficult considering the inherent limitation of using a claim-based database. The gene discussed is ESR1; the disease is breast carcinoma.